INTRODUCTION
As recently as 1985 a survey of the treatment of primary breast cancer in the United Kingdom showed that 84% of surgeons still preferred mastectomy [1] . Many surgeons are reluctant to adopt partial mastectomy or local excision because they fear an increased incidence of local recurrence. There has been however, over a number of years, increasing interest in conserving the breasts of women with early disease.
The pioneer work of Keynes was set out in a number of papers between 1927 and 1937 [2, 3] . He treated both primary and recurrent tumours by conservative surgery and radium needle implants, with a local recurrence rate of 8%. Atkins [4] reported the results of a trial of wide excision (extended tylectomy) and radiotherapy; Crile [5] in the United States advocated partial mastectomy rather than radical surgery; and in France Calle [6] and Pierquin [7] , were treating patients with excision biopsy and radiotherapy after the pioneering work of Baclesse [8] in the late 1940s and early 1950s.
In the mid-seventies some patients in our unit with medially placed lesions underwent local excision followed by radiotherapy. In [10] .
However the best way to achieve local control has produced fierce debate for nearly a century. The [12] . A high proportion of breast cancers are found to be multicentric on pathological examination of mastectomy specimens [13, 14, 15] . This has strengthened the argument for mastectomy. However In the absence of any clear difference in survival, morbidity or cost, there is no need for a mutilating operation. In the future it may be possible to select patients for whom radiotherapy is not necessary, and then the true cost benefit may be seen, together with a significant reduction in morbidity.
CONCLUSION
We report the results of 96 cases of early breast cancer treated by a wide local excision and radical radiotherapy. These are preliminary results and long term follow-up will be necessary before we can draw any conclusions about an effect on survival. At present we find a local recurrence rate of 9% encouraging and will continue to offer this treatment option to women with early breast cancer.
